SI1966238T1 - Variante interlevkina-12P40 z izboljšano stabilnostjo - Google Patents

Variante interlevkina-12P40 z izboljšano stabilnostjo

Info

Publication number
SI1966238T1
SI1966238T1 SI200631366T SI200631366T SI1966238T1 SI 1966238 T1 SI1966238 T1 SI 1966238T1 SI 200631366 T SI200631366 T SI 200631366T SI 200631366 T SI200631366 T SI 200631366T SI 1966238 T1 SI1966238 T1 SI 1966238T1
Authority
SI
Slovenia
Prior art keywords
interleukin
polypeptides
improved stability
variants
modified
Prior art date
Application number
SI200631366T
Other languages
English (en)
Inventor
Gordon D Webster
Suzanne P Mckenzie
Kin-Ming Lo
Pascal Andre Stein
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SI1966238T1 publication Critical patent/SI1966238T1/sl

Links

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/43—Processing of content or additional data, e.g. demultiplexing additional data from a digital video stream; Elementary client operations, e.g. monitoring of home network or synchronising decoder's clock; Client middleware
    • H04N21/435—Processing of additional data, e.g. decrypting of additional data, reconstructing software from modules extracted from the transport stream
    • H04N21/4353—Processing of additional data, e.g. decrypting of additional data, reconstructing software from modules extracted from the transport stream involving decryption of additional data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q20/00—Payment architectures, schemes or protocols
    • G06Q20/08—Payment architectures
    • G06Q20/10—Payment architectures specially adapted for electronic funds transfer [EFT] systems; specially adapted for home banking systems
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0207—Discounts or incentives, e.g. coupons or rebates
    • G06Q30/0215—Including financial accounts
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0207—Discounts or incentives, e.g. coupons or rebates
    • G06Q30/0226—Incentive systems for frequent usage, e.g. frequent flyer miles programs or point systems
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/04—Billing or invoicing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q40/00—Finance; Insurance; Tax strategies; Processing of corporate or income taxes
    • G06Q40/12—Accounting
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L41/00—Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks
    • H04L41/32—Specific management aspects for broadband networks
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/10—Flow control; Congestion control
    • H04L47/24—Traffic characterised by specific attributes, e.g. priority or QoS
    • H04L47/2491—Mapping quality of service [QoS] requirements between different networks
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/45—Management operations performed by the client for facilitating the reception of or the interaction with the content or administrating data related to the end-user or to the client device itself, e.g. learning user preferences for recommending movies, resolving scheduling conflicts
    • H04N21/462—Content or additional data management, e.g. creating a master electronic program guide from data received from the Internet and a Head-end, controlling the complexity of a video stream by scaling the resolution or bit-rate based on the client capabilities
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/60—Network structure or processes for video distribution between server and client or between remote clients; Control signalling between clients, server and network components; Transmission of management data between server and client, e.g. sending from server to client commands for recording incoming content stream; Communication details between server and client 
    • H04N21/61—Network physical structure; Signal processing
    • H04N21/6106—Network physical structure; Signal processing specially adapted to the downstream path of the transmission network
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/80—Generation or processing of content or additional data by content creator independently of the distribution process; Content per se
    • H04N21/85—Assembly of content; Generation of multimedia applications
    • H04N21/854—Content authoring
    • H04N21/8549—Creating video summaries, e.g. movie trailer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L41/00—Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks
    • H04L41/50—Network service management, e.g. ensuring proper service fulfilment according to agreements
    • H04L41/5003—Managing SLA; Interaction between SLA and QoS
    • H04L41/5019—Ensuring fulfilment of SLA

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Accounting & Taxation (AREA)
  • Finance (AREA)
  • General Health & Medical Sciences (AREA)
  • Development Economics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Strategic Management (AREA)
  • Signal Processing (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • Economics (AREA)
  • Multimedia (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Marketing (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Databases & Information Systems (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
SI200631366T 2005-12-30 2006-12-20 Variante interlevkina-12P40 z izboljšano stabilnostjo SI1966238T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75538205P 2005-12-30 2005-12-30
PCT/EP2006/012301 WO2007076933A1 (en) 2005-12-30 2006-12-20 Interleukin-12p40 variants with improved stability
EP20060846989 EP1966238B1 (en) 2005-12-30 2006-12-20 Interleukin-12p40 variants with improved stability

Publications (1)

Publication Number Publication Date
SI1966238T1 true SI1966238T1 (sl) 2012-08-31

Family

ID=38049414

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631366T SI1966238T1 (sl) 2005-12-30 2006-12-20 Variante interlevkina-12P40 z izboljšano stabilnostjo

Country Status (18)

Country Link
US (3) US7872107B2 (sl)
EP (1) EP1966238B1 (sl)
JP (1) JP5175214B2 (sl)
KR (1) KR101343682B1 (sl)
CN (1) CN101351475B (sl)
AT (1) ATE555125T1 (sl)
AU (1) AU2006332138B2 (sl)
BR (1) BRPI0620648B1 (sl)
CA (1) CA2635618C (sl)
CY (1) CY1112884T1 (sl)
DK (1) DK1966238T3 (sl)
EA (1) EA015338B1 (sl)
ES (1) ES2384055T3 (sl)
PL (1) PL1966238T3 (sl)
PT (1) PT1966238E (sl)
SI (1) SI1966238T1 (sl)
WO (1) WO2007076933A1 (sl)
ZA (1) ZA200806611B (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
PT1366067E (pt) 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
HU229098B1 (hu) 2001-12-04 2013-07-29 Merck Patent Gmbh Megváltoztatott szelektivitású immuncitokinek
PT1699822E (pt) 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
BRPI0417916A (pt) * 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
ES2384055T3 (es) * 2005-12-30 2012-06-28 Merck Patent Gmbh Variantes de la interleucina-12p40 con estabilidad mejorada
US20100048482A1 (en) * 2008-08-15 2010-02-25 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
AU2009306711A1 (en) * 2008-10-21 2010-04-29 Merck Patent Gmbh Cancer treatments with radiation and immunocytokines
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
NO2709651T3 (sl) 2011-05-19 2018-03-03
AU2015221181B2 (en) * 2014-02-19 2020-08-20 Merck Patent Gmbh Cancer-targeted IL-12 immunotherapy
HUE061077T2 (hu) 2016-05-18 2023-05-28 Modernatx Inc Interleukin-12 (IL12) kódoló polinukleotidok és felhasználásuk
CN106533815B (zh) * 2017-01-13 2019-10-29 邦彦技术股份有限公司 基于能力特征的网关管控方法及装置
CN108574635B (zh) 2017-03-09 2021-06-22 华为技术有限公司 一种路由优先级配置方法、设备以及控制器
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
AU2018298063A1 (en) 2017-07-03 2020-02-20 Torque Therapeutics, Inc. Polynucleotides encoding immunostimulatory fusion molecules and uses thereof
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CN110264184B (zh) * 2019-06-28 2021-07-23 Oppo（重庆）智能科技有限公司 支付控制方法及相关产品
CA3157024A1 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
WO2022155263A2 (en) * 2021-01-12 2022-07-21 Askgene Pharma Inc. Chimeric molecules comprising il-12 agonist polypeptide
KR20240035556A (ko) * 2021-07-19 2024-03-15 추가이 세이야쿠 가부시키가이샤 융합 폴리펩타이드를 이용하는 프로테아제 매개성의 표적 특이적 사이토카인 송달
EP4402158A2 (en) * 2021-09-17 2024-07-24 Bicara Therapeutics Inc. Caix targeting il-12 fusion proteins and methods of use thereof
WO2023242769A1 (en) * 2022-06-17 2023-12-21 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins
WO2024099445A1 (zh) * 2022-11-10 2024-05-16 康立泰生物医药(青岛)有限公司 聚乙二醇定点修饰异源聚体蛋白或多肽及其制备方法与应用

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US647717A (en) * 1897-12-17 1900-04-17 Guilford S Wood Rotary engine.
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US5082658A (en) * 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0294703B1 (en) 1987-06-10 1995-05-10 Dana-Farber Cancer Institute, Inc. Bifunctional antibody constructs and method for selectively destroying cell populations
US5064646A (en) 1988-08-02 1991-11-12 The University Of Maryland Novel infectious bursal disease virus
PH26813A (en) 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
DE3812605A1 (de) 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DE69034022T2 (de) 1989-09-20 2003-07-10 Abbott Laboratories, Abbott Park Verfahren zur Herstellung von Fusionsproteinen
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
ATE163675T1 (de) * 1989-12-22 1998-03-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991013166A1 (en) 1990-03-02 1991-09-05 Abbott Biotech, Inc. Antibody constructs with enhanced binding affinity
CA2082804A1 (en) 1990-07-27 1992-01-28 Theodore Maione Methods and compositions for treatment of angiogenic diseases
CA2095836C (en) 1990-11-09 1999-04-06 Stephen D. Gillies Cytokine immunoconjugates
WO1992008801A1 (en) 1990-11-09 1992-05-29 Abbott Laboratories Bridging antibody fusion constructs
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
CA2095852C (en) 1990-12-05 2001-05-08 Uffe Lovborg Proteins with changed epitopes and methods for the production thereof
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
US6797492B2 (en) * 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
WO1993003157A1 (en) 1991-07-29 1993-02-18 Dana Farber Cancer Institute Plasmids for the rapid preparation of modified proteins
WO1993005169A1 (en) 1991-08-30 1993-03-18 Fred Hutchinson Cancer Research Center Hybrid cytokines
US20020037558A1 (en) * 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US6627615B1 (en) * 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
WO1993024640A2 (en) * 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
DE4228839A1 (de) 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
AU6776194A (en) 1993-04-28 1994-11-21 Hybritech Incorporated Method for creating optimized regulatory regions affecting protein expression and protein trafficking
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
ES2166368T3 (es) 1993-12-24 2002-04-16 Merck Patent Gmbh Inmunoconjugados.
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US6148321A (en) * 1995-05-05 2000-11-14 Intel Corporation Processor event recognition
AU5985996A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
AU1407997A (en) 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1997030089A1 (en) 1996-02-13 1997-08-21 Regents Of The University Of California Novel antibody-cytokine fusion protein, and methods of making and using the same
US5922685A (en) * 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
JPH1187664A (ja) * 1997-04-28 1999-03-30 Nippon Steel Corp 半導体装置及びその製造方法
ES2258817T3 (es) * 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
WO1999003887A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
EP1037927B1 (en) * 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
CN1318092C (zh) * 1998-04-15 2007-05-30 利思进药品公司 含有抗体－细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
CA2328081A1 (en) * 1998-04-17 1999-10-28 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
EP1088888A4 (en) 1998-05-14 2005-03-16 Merck Patent Gmbh MERGED PROTEIN
ATE462725T1 (de) * 1998-08-25 2010-04-15 Merck Patent Gmbh Expression und export von angiostatin und endostatin als immunofusins
US6646113B1 (en) * 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) * 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
ID30327A (id) * 1999-01-07 2001-11-22 Lexigen Pharm Corp EKSPRESI DAN EKSPOR PROTEIN-PROTEIN ANTI OBESITAS SEBAGAI PROTEIN-PROTEIN FUSI Fc
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
HUP0201474A3 (en) * 1999-05-19 2002-11-28 Lexigen Pharmaceuticals Corp L Expression and export of interferon-alpha proteins as fc fusion proteins
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) * 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
IL148300A0 (en) * 1999-09-09 2002-09-12 Schering Corp Mammalian cytokines; related reagents and methods
JP2001161378A (ja) * 1999-10-01 2001-06-19 Toray Ind Inc タンパク質の高純度製造法、インターロイキン１２、インターロイキン１２の活性を阻害するタンパク質、哺乳動物の免疫疾病治療剤および免疫疾病治療方法
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
WO2001058957A2 (en) * 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1361892A4 (en) 2001-01-17 2004-10-13 Trubion Pharmaceuticals Inc BINDING DOMAIN FUSION PROTEIN Immunoglobulin
EP1392826A2 (en) * 2001-01-18 2004-03-03 MERCK PATENT GmbH Bifunctional fusion proteins with glucocerebrosidase activity
MXPA03007316A (es) 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
KR20040074587A (ko) * 2001-02-19 2004-08-25 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 인공 단백질
PT1366067E (pt) * 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
KR100900166B1 (ko) * 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
HU229098B1 (hu) * 2001-12-04 2013-07-29 Merck Patent Gmbh Megváltoztatott szelektivitású immuncitokinek
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
PT1699822E (pt) * 2003-12-30 2008-07-30 Merck Patent Gmbh Proteínas de fusão de il-7
BRPI0417916A (pt) * 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
DK1706428T3 (da) * 2004-01-22 2009-11-30 Merck Patent Gmbh Anti-cancer-antistoffer med reduceret komplementfiksering
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ES2342964T3 (es) * 2004-12-09 2010-07-20 Merck Patent Gmbh Variantes de la interleucina-7 con inmunogenicidad reducida.
ES2384055T3 (es) 2005-12-30 2012-06-28 Merck Patent Gmbh Variantes de la interleucina-12p40 con estabilidad mejorada

Also Published As

Publication number Publication date
WO2007076933A1 (en) 2007-07-12
AU2006332138B2 (en) 2012-03-22
ATE555125T1 (de) 2012-05-15
PL1966238T3 (pl) 2012-09-28
AU2006332138A1 (en) 2007-07-12
BRPI0620648A8 (pt) 2019-01-15
ES2384055T3 (es) 2012-06-28
US20070154453A1 (en) 2007-07-05
CN101351475B (zh) 2013-05-15
KR101343682B1 (ko) 2013-12-20
CA2635618A1 (en) 2007-07-12
US7872107B2 (en) 2011-01-18
CN101351475A (zh) 2009-01-21
KR20080090483A (ko) 2008-10-08
EP1966238A1 (en) 2008-09-10
US20110097792A1 (en) 2011-04-28
PT1966238E (pt) 2012-07-31
BRPI0620648A2 (pt) 2011-11-22
EP1966238B1 (en) 2012-04-25
JP5175214B2 (ja) 2013-04-03
DK1966238T3 (da) 2012-07-16
EA200870131A1 (ru) 2008-12-30
CY1112884T1 (el) 2016-04-13
ZA200806611B (en) 2009-12-30
JP2009521911A (ja) 2009-06-11
US20130034518A1 (en) 2013-02-07
US9029330B2 (en) 2015-05-12
US8188248B2 (en) 2012-05-29
CA2635618C (en) 2015-10-06
BRPI0620648B1 (pt) 2022-12-20
EA015338B1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
ZA200806611B (en) Interleukin-12P40 variants with improved stability
EP1778714A4 (en) PROCESS FOR THE PREPARATION AND USE OF RECOMBINANT SPORES OF BACILLUS THURINGIENSIS
IL209494A (en) Formulations of insulin oligomeric monoconogues and their use
HK1103931A1 (en) Profile-rail system
GB2399008B (en) Cellular chair construction
EP1487853A4 (en) SECRETION, TRANSCRIPTION AND SPORULATION GENES IN BACILLUS CLAUSII
PT2184360E (pt) Novos polipéptidos cristalinos de bacillus thuringiensis, polinucleótidos e composições destes
EP1830564A4 (en) A CAMERA WEARING PORTABLE TERMINAL WITH FOCUS ADJUSTMENT
WO2007027714A3 (en) Engineered anti-il-23 antibodies
EP1578930A4 (en) CNGH0004 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES
MX2007007613A (es) Formulaciones farmaceuticas.
AU2003303222A8 (en) Mutant proteins with increased secretion
PL375202A1 (en) Cytokine polypeptides
EP1497423A4 (en) MUTANT MCP-1 PROTEINS, ANTIBODIES, COMPOSITIONS, PROCESSES AND USES
AU307987S (en) Adjustable staircase spine
GB0413810D0 (en) Adex chair
AU300892S (en) Tables
AU300895S (en) Entertainment unit
AU300901S (en) Coffee table
AU2003251425A8 (en) Mahoganoid polypeptides, and related compositions and methods
PL376826A1 (pl) Przekładka amortyzująco-izolująca, zwłaszcza podszynowa
AU300896S (en) Entertainment unit
AU300894S (en) Entertainment unit
AU300893S (en) Entertainment unit
GB0314431D0 (en) Portable sleeper/armrest